---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-21-005572"
form_type: "8-K"
ticker: "CLDX"
cik: "0000744218"
company_name: "Celldex Therapeutics, Inc."
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T22:05:14.367002+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Celldex reports Q2 2021 net loss of $13.4M; raises $287.5M in follow-on offering

## Summary
- Net loss $13.4M ($0.34/share) vs $11.0M ($0.50/share) in Q2 2020; revenue $3.5M vs $0.2M.
- Cash $164.0M at June 30, 2021; July follow-on offering added $287.5M gross ($270M net), extending runway through 2025.
- CDX-0159 Phase 1b: 95% complete response in chronic inducible urticaria; 87% skin mast cell depletion with single dose.
- Plan to initiate CDX-0159 study in prurigo nodularis in Q4 2021 and subcutaneous formulation Phase 1 in Q3 2021.
- CDX-1140 expansion cohorts recruiting; CDX-527 dose escalation completed, expansion cohorts planned.

## SEC filing metadata
- accession: 0001171843-21-005572
- form_type: 8-K
- ticker: CLDX
- cik: 0000744218
- company_name: Celldex Therapeutics, Inc.
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/744218/000117184321005572/0001171843-21-005572-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/744218/000117184321005572/f8k_080521.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-21-005572
- JSON: https://secwatch.observer/filing/0001171843-21-005572.json
- Plain text: https://secwatch.observer/filing/0001171843-21-005572.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.